 "lupin")
Drug firm Lupin on Tuesday said it has received approval from the US health regulator to market Doxycycline Capsules used to treat bacterial infections in the American market.
The drug firm has received tentative approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Doxycycline Capsules, 40 mg, a generic equivalent of Galderma Laboratories' Oracea capsules, Lupin Ltd said in a statement.
As per IQVIA MAT September 2022 data, Doxycycline capsules had estimated annual sales of USD 215 million in the US market.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
